haloperidol (standard)

Haloperidol (Standard) is a reference standard for research and analysis in studies involving Haloperidol. Haloperidol is an effective dopamine D2 receptor antagonist that can be used to induce models of tardive dyskinesia and Parkinson’s disease.

VU0477886 is a potent mGlu4 positive allosteric modulator (PAM) with robust efficacy in a standard preclinical Parkinson's disease model, haloperidol-induced catalepsy (HIC).

Reduced Haloperidol (Standard) is a reference standard for research and analysis in studies involving Reduced Haloperidol. Reduced haloperidol is an active metabolite of haloperidol . It is formed via reduction of haloperidol by ketone reductase. Reduced haloperidol inhibits radioligand binding to sigma-1 and dopamine D2 receptors (Kis = 1.4 and 31 nM, respectively) and stimulates brain-derived neurotrophic factor (BDNF) secretion from CCF-SSTG1 and U87MG astrocytic glial cells. It also inhibits norepinephrine, dopamine, and serotonin (5-HT) reuptake (Kis = 21, 25, and 33 μM, respectively, in COS-7 cells expressing the human transporters). Reduced haloperidol (0.5 mg/kg) increases latency to paw withdrawal in mouse models of capsaicin- but not force-induced mechanical hypersensitivity.

Haloperidol-13C6 (Standard) is a reference standard of Haloperidol-13C6 intended for quantitative analysis, quality control, and related biochemical research applications.

Haloperidol-[13C6] (Standard) is a reference standard of Haloperidol-[13C6] intended for quantitative analysis, quality control, and related biochemical research applications.

Reduced Haloperidol-[D4] (Standard) is a reference standard of Reduced Haloperidol-[D4] intended for quantitative analysis, quality control, and related biochemical research applications.

Haloperidol D4 (Standard) is a reference standard of Haloperidol D4 intended for quantitative analysis, quality control, and related biochemical research applications.